Our Take
This is a regulatory clearance, not a clinical breakthrough; the drug's efficacy mirrors EpiPen, but the needle-free format addresses a documented barrier to timely use.
Why it matters
Anaphylaxis affects an estimated 761 per 100,000 European children annually (per the source), and fear of needles delays or prevents treatment entirely. A simpler delivery method expands the eligible population and removes a known friction point from emergency response.
Do this week
Pediatricians and allergy specialists: update your anaphylaxis response protocols and patient education materials this week to include EURneffy as a first-line option for children 4–9 years old, so caregivers know the needle-free alternative exists before a crisis.
MHRA clears lower-dose nasal spray for younger children
The UK Medicines and Healthcare products Regulatory Agency approved a 1mg formulation of EURneffy, ALK-Abelló's adrenaline nasal spray, for children aged 4 years and above weighing between 15kg and 30kg. This extends the product's reach beyond the previously approved 2mg dose, which was cleared in July 2025 for children and adults 10 years and older weighing 30kg or more (per company statement).
EURneffy is a needle-free alternative to injectable adrenaline auto-injectors like EpiPen. ALK acquired European and Canadian rights to the drug in November 2025 for $145m upfront from developer ARS Pharmaceuticals, which retained US marketing rights under the brand Neffy. The US FDA also widened the pediatric label for the spray in March 2026 (per regulatory filings).
Anaphylaxis—a severe, immediate allergic reaction to food, insect stings, or medications—affects an estimated 761 per 100,000 children annually in Europe, with food allergies driving more than two-thirds of cases (per epidemiological data cited in the source). Adrenaline is the established first-line treatment and must be administered immediately at symptom onset.
Needle fear is a real barrier to timely treatment
Injectable auto-injectors are clinically effective but face documented adoption and usability friction. Fear of needles, hesitancy to act, and incorrect administration mean patients often do not carry the device or delay using it when symptoms appear. A nasal spray removes the needle barrier and offers a simpler self-administration route, lowering the threshold for caregivers to use it at the first sign of reaction.
The expansion to younger children (ages 4–9) addresses a population segment previously limited to injectable options. This regulatory clarity matters because it allows physicians and families to plan ahead and removes uncertainty about treatment options during the critical early years when food allergies are most common.
Market analysts project Neffy (the US brand) will reach $1bn in global net sales by 2032 (per analyst estimate from GlobalData, parent company of the source). Full-year 2025 sales were $20.3m (company-reported), suggesting early traction in markets where it is already available.
What clinicians and families need to do now
Pediatricians, allergists, and emergency medicine teams should update anaphylaxis response protocols to include EURneffy as a named option for eligible children. Patient education materials—especially those given to families with young children at risk of severe allergic reactions—should mention the nasal spray alternative explicitly, so caregivers understand they have a choice and the needle-free option exists before a crisis forces a decision.
For families: if your child is 4 years or older and weighs between 15kg and 30kg, ask your allergist whether EURneffy is appropriate. Needle anxiety in young children is real and measurable; a treatment option your child is more likely to carry and use without fear has material value in emergency outcomes.